摘要
为了解吲达胺(Indapamide)老年人药代动力学特点,本文选择了7位老年健康志愿者和8位青年志愿者。单次口服吲达胺7.5mg,于服药前及服药后30min,1,2,3,4,5,6,8,12,16,24h多次取血,以高效液相色谱测定血药浓度。t1/2β在老年组较青年组延长,分别为33.3±8.0 h及25.1±5.0 h(p<0.05),Vd在老年组较青年组增大,分别为73.0±19.31及54.3±10.61(p<0.05),Vd增大与老年人体内脂肪含量增加有关,而t1/2β的延长则继发于Vd的增大。其它药代动力学参数两组无差异。
Since the appearance of indapamide in 1970' s, it has beenwidely accepted because of its effectiveness , convenience and safety, whi-ch makes it espacilly suitable in anti-hypertensive treatment of the elde-rly people. Up till now, there is no report on the pharmacokinetics ofthis drug in aged people although the body structure and function of thesepeople are different from those of the young people. This study focus onthis area in order to give guidelines for the proper use of indapamide inelderly hypertensives. Seven normal elderly volunteers (average age 65. 1 years old) andeight normal young volunteers (average age 25. 9 years old) were includedin this study. Blood samples were taken before and 0.5, 1, 2, 3, 4,5, 6 , 8, 12, 16 and 24h after 7.5 mg indapamide administratedorally. Plasma concentration was determined with HPLC. All the volun-teers have two compartment open model except one in young group, whohas one compartment open model. In elderly and young group, t1/2β are 33. 8 ±8.0 hours and 25. 1±5.0hours respectively (p<0. 05) and Vd are 73. 0 ±19. 3 litres and 54. 3± 10.6litres respectively (p<0. 05). Other pharmacokinetic parameters such ast_(1/2) K_α, t_(1/2α), AUC, tmax, Cmax and K_(10) show no difference betweentwo groups. The enlarged Vd, which accounts for the prolongation ofT_(1/2β), is caused by the increase of lipidic tissue in elderly people. Ourresults suggest that the dosage of indapamide should be adjusted in theanti-hypertensive treatment in aged people in case of drug retention.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1991年第3期161-165,共5页
The Chinese Journal of Clinical Pharmacology
关键词
吲达胺
药代动力学
老年人
降压药
indapamide
pharmacokinetics
anti-hypertensive drug
elderly people
